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 Introduction 
Currently, simultaneous pancreas-kidney transplantation (SPK Tx) is the treatment of 
choice in selected patients with type 1 diabetes mellitus (DM1) and terminal kidney 
failure (TRF). A functioning SPK transplant allows dialysis and insulin therapy to be 
discontinued and stabilizes or improves the complications of DM1. Nevertheless, to a 
greater or lesser degree, these complications (physical and psychological alterations, 
secondary effects of immunosuppressive therapy and the need for lifelong medication 
and medical follow-up) can persist after SPK Tx. Health professionals have mainly 
investigated the clinical features of transplant recipients. However, in the last few years, 
interest in analyzing perceived health and health-related quality of life (QoL) has 
increased. This latter concept includes the features of QoL most closely associated with a 
particular disease, its treatment and follow-up and therefore those elements most 
susceptible to modification by the health system. 
The general aim of this study was to measure health-related QoL in our 
population with SPK Tx and to determine whether there are significant differences 
between these patients and those with DM1 and TRF who continue to receive renal 
replacement therapy (RRT) and insulin therapy. More specific aims were to evaluate 
whether there are significant differences between the study groups and the means of the 
Spanish reference population in the distinct dimensions of a QoL questionnaire and 
whether other variables such as age, sex, years’ duration of DM1, length of dialysis, and 
time since SPK Tx significantly affect health-related QoL. 
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Patients and methods 
From 2004-2005, we performed a cross-sectional study of health-related QoL in 
69 patients who underwent SPK Tx in Hospital Clínico de Barcelona from 1998-2002 
and in 34 patients with DM1 and TRF undergoing RRT in hospitals or health centers in 
Catalonia (Spain) and included on the waiting list for an SPK or kidney transplant alone. 
Inclusion criteria were maintained function in both grafts in SPK transplant recipients, 
and DM1 and TRF, age equal to or less than 55 years, and length of RRT longer than 1 
year in patients under RRT. Before patients receiving RRT were included in the study, 
the consultant in charge of each patient confirmed that the patient had no severe vascular 
or neuropathic complications (potentially treatable severe peripheral vascular disease or 
coronary heart disease, or disabling motor or autonomic neuropathy). 
To evaluate QoL, the Spanish version of the Medical Outcomes Study 36-Item 
Short Form Health Survey (SF-36) was selected as it is one of the most widely used 
instruments, all articles published on its metric properties support is reliability, validity 
and sensitivity, and no differences have been found in its internal consistency between 
self-administered questionnaires and those administered through interview (1). The SF-
36, developed by Ware (2, 3) and adapted and validated by Alonso et al. (4), is a generic 
QoL questionnaire containing 36 items grouped in the following eight scales: physical 
functioning, role limitations-physical, bodily pain, general health, vitality, social 
functioning, role limitations-emotional, and mental health. There is also an item that 
assesses perception of changes in health status compared with health 1 year previously.  
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In addition to the SF-36, the following variables were recorded: type of treatment 
(SPK Tx or RRT), type of RRT (haemodialysis or peritoneal dialysis), sex, age, DM1 
duration, and length of RRT. All the questionnaires were self-administered except in four 
patients in whom telephone interviews were carried out.  
For the data analysis, the instructions for the standardization of content and 
scoring of the Spanish version of the SF-36 were followed (5). To calculate the scores, 
the following steps were performed: scoring was reversed in 10 items requiring this step 
so that high scores always indicated better health; secondly, the sum of all the items 
composing each scale was calculated; and thirdly, linear transformation of crude scores 
was carried out to obtain scores on a scale of 0-100. Thus, for each dimension, the items 
were codified, summed, and transformed on a scale ranging from 0 (worst health status 
on this dimension) to 100 (best health status).  
 
Statistical analysis 
Descriptive analysis of the variables was performed by calculating frequencies for 
qualitative variables and means, standard deviation, median and range for quantitative 
variables, as well as 95% confidence intervals for means. To analyze the association 
between the scores obtained on the SF-36 and clinical and sociodemographic variables, 
the chi-squared test or Fisher's exact test were used. To compare means, Student's t-test 
or the Mann-Whitney U-test were used, depending on the sample size of each group and 
the number of different values observed in each of the variables. 
 
 PAGE 4 
Page 4 of 22Clinical Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Subsequently, to determine whether there were statistically significant differences 
in QoL dimensions between SPK transplant recipients and patients under RRT, adjusted 
by other variables that could influence these dimensions, a multiple linear regression 
model and/or two-way ANOVA with covariables and interaction effects were 
constructed. Independent variables were sex, age, duration of DM1, study group, and 
length of dialysis. In variables significantly departing from normal distribution, 
transformation of the dependent variable was performed. In all the models constructed, 
possible multicolinearity and the potential effects of interaction were studied. Non-
significant variables and interaction effects were removed from the model. In dimensions 
showing few values in their distribution, an ordinal regression (PLUM) model was 
constructed. The binomial test was used to compare the scores obtained on the QoL 
dimensions with the means of the Spanish reference population according to sex and age 
and according to the year in which SPK Tx was performed. 
 
Results 
Sixty-nine SPK transplant recipients and 34 patients receiving RRT met the 
inclusion criteria. All patients completed the questionnaire (self-administered in 99 and 
performed through telephone interview in four). No significant differences were found 
between the two groups in age and sex. In contrast, significant differences were found in 
DM1 duration and length of RRT (Table 1). 
Perception of current health status compared with health 1 year previously was 
better in SPK transplant recipients than in patients under RRT (Table 2). QoL was higher 
in SPK transplant recipients than in patients receiving RRT, with significant differences 
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in all dimensions (Table 3). In both groups, QoL was lower in women than in men 
(Tables 4 and 5). 
Multivariate analysis revealed that SPK Tx was significantly associated with 
improved QoL in all dimensions of the SF-36. In both groups, sex, age and DM1 duration 
were significantly related to QoL. Female sex was negatively associated with the 
dimensions of mental health, bodily pain, vitality, role limitation-emotional, and physical 
functioning. Age was positively associated with mental health and a no significant 
negative association was found with general health (p=0.053). Duration of DM1 was 
negatively associated with the dimensions of mental health and bodily pain (Table 6). 
Significant differences were observed according to the year in which SPK Tx was 
performed.  In almost all domains of the SF-36, the highest scores corresponded to the 
most recently transplanted patients (Table 7). 
Comparison of the results with the means of the reference population showed 
significant differences according to study group and sex. In SPK transplant recipients, 
men scored significantly lower than the reference population in the dimensions of general 
health, role limitations-physical and role limitations-emotional but scored significantly 
higher in the dimension of vitality. Women with SPK transplants scored significantly 
lower than the reference population in the dimension of general health. 
In patients undergoing RRT, men scored significantly lower than the reference 
population in the dimensions of physical functioning, bodily pain, general health, and 
vitality. Women undergoing RRT scored significantly lower than the reference 
population in all dimensions of the SF-36 (Table 8). 
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Comparison of the means obtained in SPK transplant recipients with those for the 
reference population according to the year in which transplantation was performed 
revealed that patients who received a transplant in the last year of the study, i.e., those 
most recently transplanted, showed higher scores than the reference population on the 
dimensions of role limitations-physical, vitality, and role limitations-emotional. SPK 
transplant recipients scored significantly lower than the reference population in the 
domains of physical functioning in 2000 and 2002, in role limitations-physical in 1999 
and in general health in 1999, 2000 and 2001 (Table 9). 
 
Discussion 
In the present study, QoL was higher in SPK transplant recipients than in patients 
receiving RRT in all dimensions of the SF-36 and this result held constant when 
adjustment was made for other variables such as type of treatment (SPK Tx or RRT), sex, 
age, DM1 duration, and length of RRT. These results coincide with those studies that 
have shown the effectiveness of SPK Tx in improving QoL (6-8) and with other studies 
that have shown the association between RRT and increased stress, anxiety, impaired self 
image, and reduced QoL (9-11. 
Women expressed a greater degree of physical and emotional limitation and 
therefore lower QoL than men, independent of treatment. Some studies have found no 
significant differences according to sex and have even found higher QoL in women, 
mainly in mental health (12). However in most studies, female sex has been associated 
with poorer perceived health and QoL, both in healthy individuals and in those with 
disease (1, 13).  
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Age has frequently been associated with worse QoL (1, 14,15). However, in the 
present study, greater age was associated with better QoL, possibly because the patients 
studied were not elderly. The negative effects of age on QoL could be due not only to the 
effect of disease but also to that of the functional deterioration found in the elderly. In 
addition, as suggested by other authors (16), the SF-36 may be able to discriminate 
between the effect of disease and treatment and that of age on QoL. 
The association between age and better QoL has been observed in studies of 
patients under RRT and in kidney transplant recipients (12,16) and is in agreement with 
other studies demonstrating that having a chronic disease and being young is associated 
with psychological disorders and impaired QoL (17). These findings could be explained 
by the difficulty of young people in coping with chronic health problems while 
attempting to forge a life. Patients receiving prolonged treatment may have difficulties in 
adapting to the disease, its treatment, lifestyle limitations and associated stigma (18). In 
the present study, although both groups underwent prolonged treatment, RRT was 
associated with greater dependency and more evident stigma. 
Comparison of the results obtained with the means of the reference population 
revealed that both SPK transplant recipients and patients under RRT had worse QoL, 
although male SPK transplant recipients scored better than the reference population on 
the dimension of vitality. In a recent qualitative study, some SPK transplant recipients 
reported that after transplantation they had recovered their “health”, as well as their 
enjoyment of life, social relationships and, in some cases, sexual and reproductive 
function and occupational activity (14). However, the present study would indicate that, 
despite the perception of “cure” and the improvement achieved, SPK transplant recipients 
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show a variety of symptoms and require treatment and medical follow-up, all of which 
reduces their QoL, mainly the dimension of general health. Other authors have revealed 
that the improvement in QoL after Tx does not reach QoL levels in the general 
population (19). 
Women with SPK transplants obtained lower scores and therefore showed worse 
QoL than men with SPK transplants in all dimensions. However fewer significant 
differences with respect to the reference population were observed in women. This result 
could be due to the smaller number of women than men in this study, reducing statistical 
power.  
The highest QoL scores were observed in the most recently transplanted patients. 
These patients had a greater perception of improvement compared with health 1-year 
previously, showed higher values than the reference population in several dimensions, 
and showed a negative significant difference only in the dimension of physical 
functioning. These results coincide with those of other studies that have revealed 
decreased QoL in transplanted patients over time (12,20). The study period in the present 
study comprised the beginning of 1998 to the end of 2002, with data collection in 2004. 
Consequently, SPK transplant recipients had a transplant duration of between 1 and 6 
years. Patients who underwent SPK Tx in the final year of the study (2002) had a 
transplant duration of slightly more than 1 year (those transplanted at the end of 2002 and 
interviewed at the beginning of 2004) or 3 years (patients transplanted at the beginning of 
2002 and interviewed at the end of 2004), demonstrating that the improvement in QoL 
after SPK Tx is maintained after the first year.  
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These results differ from those of other studies. Some studies report that 
transplanted patients experience a state of euphoria in the first year after transplantation 
due to improvements in physical, social, occupational and sexual function (21-22) and 
that the results of QoL evaluation tend to reach a peak (21) before decreasing. Other 
studies have reported that QoL in transplant recipients undergoes temporal oscillations. A 
study in kidney transplant recipients observed that QoL improved during the first 6 
months and then deteriorated before improving again after the first 3 years (23). Pérez 
San Gregorio et al. (22) reported that transplant recipients pass through three phases: a 
first phase in which they require treatment and intense medical follow-up and experience 
difficulties in social and occupational integration, fear of graft rejection, and possible 
alterations in family dynamics as a result of transplantation; a second phase of adaptation, 
and a third phase of mental and physical exhaustion in which psychological disturbances 
increase. This latter phase begins some time after the first 2 years of transplantation. 
The possible limitations of this study are due to the relatively small number of 
patients studied. However, it is important to note that the sample of SPK transplant 
recipients studied represents 100% of those undergoing this surgery in the study period 
who maintained two functioning grafts, that the number of patients under RRT represents 
a high percentage, given the strict inclusion criteria applied, and that significant 
differences were detected. Socioeconomic or cultural variables that could have influenced 
the results were not taken into account. Although not all studies have found an 
association with these factors (16), socioeconomic position has been found to be 
correlated with perceived QoL (41). Finally, the SF-36 does not include some health 
factors, such as sleep disorders and cognitive, family or sexual functions. 
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Despite these limitations, multivariate analysis revealed that SPK Tx is positive 
predictive factor of QoL. We believe that this type of study is justified by the importance 
of determining the improvement in QoL after SPK Tx. Several studies have reported 
clinical improvement in patients after SPK Tx. Sustained normal blood glucose and 
HbA1 levels seem to stabilize retinopathy (25), improve neuropathy (26), protect the 
kidney transplant from the risk of recurrence of diabetic nephropathy (27), and decrease 
cardiovascular risk (28-29). However, changes in patients’ lives cannot be determined by 
clinical and biological improvements alone. 
QoL is a multidimensional concept that includes objective and subjective 
evaluation of the physical, psychological and social factors that determine well being or 
its absence.  Although controversial, the most important and reliable indicators of QoL 
are subjective, since they express the degree of well being or limitation perceived by the 
patient and the effect on QoL. Determining the factors associated with QoL in patients 
with SPK Tx and in those receiving RRT is essential for the development of strategies 
able to improve these patients’ perceived well being. Several studies have observed that 
emotional and psychological factors are the most important predictive factors in 
perceived QoL after transplantation (12,30) and that these factors can be modified by 
psychological support (31).   
The results of the present study demonstrate that SPK Tx improves QoL and that 
QoL in SPK transplant recipients continued to be better than that in patients receiving 
RRT and insulin during the study period, although QoL was lower than that in the 
reference population. Negative predictive factors of QoL were female sex, RRT and DM1 
duration. Positive predictive factors of QoL were SPK Tx and greater age. The highest 
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QoL was found in patients most recently undergoing SPK Tx, who also showed higher 
values in some domains than the reference population. Age is a positive predictive factor 
of mental health and a negative predictive factor of the dimension of role limitation-
physical. Future studies should combine QoL analysis with qualitative methodology, 
which provides more exhaustive information, serial QoL evaluations to determine 
temporal variations, and the perspective of gender to elucidate the sex differences 
observed in QoL.   
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Table 1. Age, sex, mean years’ duration of DM1 and mean length of RRT by study group  
 
Sex Age   
n 
Duration of DM1  
(before Tx) 
Length of 
RRT  Male Female  Men  Women 
SPK 
transplant 
recipients  
69 
 
23.8 + 6.3 
 
20.2 + 13.4 41 28 41.78+6.5 38.5+7.0
Patients 
under RRT  34 26.9 + 8.4 33.3 + 28.8 24 10 41.6+8.5 45.9+5.8
Significance  0.03a 0.02a 0.18b 0.31a
a t-test significance 
b Chi-squared test significance 
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Table 2. Current perceived health status compared with health 1 year previously by sex 
 
Current health status Men  Women  
 RRT SPK Tx RRT SPK Tx  
Much better than 1 year ago  1 (4.2%) 18 (43.9%) 0 (0%) 8 (28.6%) 
Somewhat better than 1 year ago  8 (33.3%) 3 (7.3%) 3 (30%) 5 (17.9%) 
More or less the same as 1 year ago  7 (29.2%) 18 (43.9%) 3 (30%) 13 (46.4%) 
Somewhat worse than 1 year ago  5 (20.8%) 2 (4.9%) 4 (40%) 2 (7.1%) 
Much worse than 1 year ago  3 (12.5%) 0 (0%) 0 (0%) 0 (0%) 
     
Fisher’s exact test  23.737 8.147 
Exact significance (bilateral) 0.001 0.025 
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Table 3. Means, standard deviation and statistical significance of the eight SF-36 dimensions in 
SPK transplant recipients and patients with DM1 under RRT (scale: 0= 100)  
 
RRT 
or  
a t-test significance 
SPK 
Tx   
Physical 
functioning  
Role-
physical Bodily pain 
General 
health  Vitality 
Social 
functioning  
Role- 
Emotional 
Mental 
health  
RRT  
(N=34) Mean 57.4506 55.1471 59.8235 35.7941 46.1176 65.4412 58.8118 61.1765
  SD 31.23815 45.13423 28.53331 18.97172 22.66457 31.84046 44.23690 23.68540
SPK  
Tx 
(N=69) 
Mean 82.8986 79.7101 77.9130 56.1594 69.1304 82.4275 77.7725 72.4638
  SD 19.23932a 33.56166b 23.65421a 19.66904a 22.67021a 23.70922b 38.63493b 21.74219a
Significance 0.001 0.008 0.001 0.001 0.001 0.013 0.017 0.018 
b U Mann-Whitney test significance 
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Table 4. Means, standard deviation and statistical significance of the eight SF-36 dimensions in 
SPK transplant recipients by sex  
 
 
 
 
 
Sex Physical 
functioning 
Role-
physical 
Bodily 
pain 
General 
health Vitality 
Social 
functioning 
Role-
emotional 
Mental 
health 
Men  
Mean 
N=41 
 
  84.1463 
  
18.93748 
 
  84.1463 
   
29.97713 
 
  82.2927 
 
20.62795
 
  57.7317 
  
19.30547 
 
  73.7805 
  
21.58647 
 
  87.8049 
 
18.64299 
 
  83.7341 
  
34.25926 
 
  79.4146 
 
17.51710SD  
Women 
Mean 
N=28 
 
  81.0714 
  
SD 19.87727 
 
  73.2143 
   
37.84017 
 
 
71.50000 
 
26.58947
 
  53.8571 
  
20.32097 
 
  62.3214 
  
22.87171 
 
  74.5536 
 
28.15346 
 
  69.0429 
  
43.44512 
 
  62.2857 
 
23.56214
Significance 0.272a 0.205b 0.065a 0.528a 0.029a 0.042b 0.175b 0.002a
a t-test significance 
b U Mann-Whitney test significance 
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Table 5. Means, standard deviation and statistical significance of the eight SF-36 dimensions in 
patients with DM1 under RRT by sex  
 
 
Sex Physical 
functioning  
Role-
physical 
Bodily 
pain 
General 
health Vitality 
Social 
functioning 
Role-
emotional 
Mental 
health 
Men  
Mean 
N=24 
SD  
  
 62.3608 
 
30.30841 
 
 68.7500 
           
43.76941 
 
 
 67.5000 
           
26.53769 
 
  37.5417 
            
18.59401 
 
  49.5000 
            
22.75473 
 
  73.9583 
            
30.15284 
 
  74.9875 
            
38.38938 
 
65.6667 
 
23.38090 
Women 
Mean 
N =10 
SD 
 
  45.6660 
 
31.81006 
 
  22.5000 
            
29.93047 
 
  41.4000 
            
25.43925 
 
  31.6000 
            
20.21111 
 
  38.0000 
            
22.75473 
 
  45.0000 
 
27.13137 
 
  19.9900 
            
32.19846 
 
  50.4000 
            
21.84389 
Significance 0.137a 0.008b 0.010a 0.013b 0.002b0.423 a 0.148 a 0.118a
 
a t-test significance 
b U Mann-Whitney test significance 
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 Table 6. Multivariate Analysis. Dimensions of mental health, physical functioning, bodily pain, 
general health, vitality, role-physical, role-emotional and social functioning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Dependent variable 
 
Independent variables Model Coefficients Significance 
Mental health a 1. (Constant) 
     Age 
     Tx SPK or RRT 
     Sex 
     DM1 duration (years)
 64,436
     ,702
 11,596
-14,608
   -, 966
<0.001 
0.036 
0.010 
0.001 
0.005 
physical functioning a 
(Transformed) 
1. (Constant) 
     Age 
     Tx SPK or RRT 
     Sex 
 
 543,42
   - 133,07
3258,98 
- 141,71  
0.001 
0.003 
<0.001 
0.083 
Bodily pain a 1. Constant) 
     Tx SPK or RRT 
     Sex 
     DM1 duration (years)
   88,351
   16,547
 - 14,032  
     - ,998
<0.001 
0.001 
0.005 
0.003 
General health  a 0.006 1. (Constant) 
     Age 
     Tx SPK or RRT 
   38,733
     - ,515
   19,128
0.053 
<0.001  
Vitalidty b  Intersection 
     Sex 
     Tx SPK or RRT 
62,314
11,471
-24,294
<0.001 
0.013 
<0.001 
Role-fhysical c DM1 duration (years) 
Age 
Sex 
2,031E-02
-5,501E-02
1,263
0.062 
0.059 
0.003 
Tx SPK or RRT -1,387 0.002 
Role- Emotional c 0.003 Sex 
Tx SPK or RRT 
1,286
0.007 -1,197
Social functioning c 0.002 Sex 1,225
0.003 Tx SPK or RRT -1,189
a Lineal Multiple Regression 
b ANOVA 
c Ordinal Regression (Plum) 
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Table 7. Mean range of SF-36 dimensions in patients SPK transplant recipients by study year  
 
 
YEAR  
 
 
 
n 
Physical 
functioning  
Role-
physical 
Bodily 
pain 
General 
health Vitality 
Social 
functioning 
Role-
emotional 
Mental 
health 
  Mean range 
1998 10 31.05 32.80 34.40 35.40 28.15 27.45 33.75 30.00
1999 13 39.08 41.62 35.04 39.15 44.50 37.58 37.15 42.69
2000 17 21.62 27.35 32.06 25.53 25.68 32.03 33.65 31.97
2001 17 37.79 32.00 33.97 33.91 35.76 31.00 30.8533.68 
12 48.88 44.75 41.08 45.13 42.54 44.58 41.29 41.002002 
  Kruskal Wallis test 
Chi-squared   
15.203 10.038 1.663 7.492 9.545 5.582 3.450 4.753
Df  4 4 4 4 4 4 4 4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asintotic 
significance. 
 .004 .040 .049 .797 .112 .233 .486 .314
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Table 8. Comparison of the values obtained in each of the SF-36 dimensions with mean values in 
the Spanish reference population by sex and SPK TX or RRT  
GROUP 
 
 
Sex 
 
 
 
n 
Physical 
functioning  
Role-
physical 
Bodily 
pain 
General 
health Vitality 
Social 
functioning 
Role-
emotional 
Mental 
health 
 
  
Exact significance binomial test (observed proportion ≤ reference population value) 
M 41 0.75  (0.46) 
0.012 
(0.29) 
0.34 
(0.41) 
0.001 
(0.83) 
0.028 
(0.32) 
0.34 
(0.41) 
0.001 
(0.22) 
0.34 
(0.41) 
 
 SPK Tx 
 
F 28 0.18  (0.64) 
0.57 
(0.43) 
0.34 
(0.61) 
0.001 
(0.86) 
0.85 
(0.46) 
0.34 
(0.61) 
0.18 
(0.36) 
0.18 
(0.64) 
M 24 0.02 (0.83) 
0.3 
(0.38) 
0.05 
(0.71) 
0.001 
(0.96) 
0.05 
(0.71) 
0.83 
(0.54) 
0.3 
(0.38) 
0.3 
(0.63) 
 
RRT 
 
F 10 0.002 (0.17) 
0.002 
(0.63) 
0.021 
(0.90) 
0.002 
(1.0) 
0.021 
(0.90) 
0.021 
(0.90) 
0.021 0.021 
(0.90) (0.10) 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Comparison of the values obtained in each of the SF-36 dimensions by SPK transplant 
recipients with mean values in the Spanish reference population by year of SPK Tx  
 
 
YEAR 
 
 
 
n 
Physical 
functioning  
Role-
physical 
Bodily 
pain 
General 
health Vitality 
Social 
functioning 
Role-
emotional 
Mental 
health 
  
Exact significance binomial test (Observed proportion ≤ reference population value) 
1998 10 0.34  (0.70) 
0.75 
(0.40) 
1.00 
(0.50) 
0.34 
(0.70) 
0.75 
(0.60) 
0.75 
(0.60) 
0.34 
(0.30) 
0.75 
(0.60) 
1999 13 1.00  (0.54) 
0.002 
(0.15) 
1.00 
(0.50) 
0.022 
(0.85) 
0.092 
(0.23) 
0.58 
(0.38) 
0.092 
(0.23) 
1.00 
(0.46) 
2000 17 0.002 (0.88) 
0.62 
(0.59) 
1.00 
(0.53) 
0.001 
(1.00) 
0.62 
(0.59) 
0.33 
(0.65) 
0.14 
(0.29) 
1.00 
(0.46) 
2001 17 0.33 (0.35) 
0.62 
(0.59) 
1.00 
(0.53) 
0.002 
(0.88) 
0.14 
((0.29) 
1.00 
(0.53) 
1.00 
(0.53) 
1.00 
(0.53) 
2002 12 0.039 (0.17) 
0.006 
(0.08) 
0.38 
(0.33) 
0.38 
(0.67) 
0.039 
(0.17) 
0.14 
(0.25) 
0.006 0.77 
(0.08) (0.42) 
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